Home > Boards > US OTC > Biotechs >

Talon Therapeutics, Inc. (TLON)

Add TLON Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/14/2019 9:52:17 AM - Followers: 97 - Board type: Free - Posts Today: 0



is since dec. 2010


Company Overview

Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - http://maps.yahoo.com/maps_result?addr=2207%20Bridgepointe%20Parkway%20Suite%20250&csz=San%20Mateo%20CA%2094404&country=United%20States" rel="nofollow">Map
Phone:                650-588-6404       
Fax: 650-588-2787
Website: http://www.talontx.com

Business Summary  

Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California


Current Pipeline




Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »

Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »

Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »

Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »


Talon Therapeutics Corporate Presentation   PDF 869.6 KB Add to Briefcase

VSLI (Vincristine Sulfate Liposomes Injection, Marqibo®) "Bridging" to Potentially Curative Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Philadelphia Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) 06/09/2011 PDF 151.1 KB Add to Briefcase
VSLI (vincristine sulfate liposomes injection) in the Treatment of Adult Subjects with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and rALLy Studies 12/05/2010 PDF 110.6 KB Add to Briefcase
Marqibo (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) 12/05/2010 PDF

and more:



  • OTC Market Tier

    Pink Quote/OTCBB
  • Primary SIC - Industry Classification

    2834 - Pharmaceutical preparations
  • State Of Incorporation

  • Jurisdiction Of Incorporation

    United States



Board of Directors

Steven R. Deitcher, M.D.
President & Chief Executive Officer

Nishan de Silva, M.D.
Principal, Warburg Pincus

Andrew K. Ferrer
Associate, Warburg Pincus

Howard P. Furst, M.D.
Partner, Deerfield Management

Jonathan S. Leff
Managing Director, Warburg Pincus

Paul V. Maier
Chief Financial Officer, Sequenom, Inc.

Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University

Robert J. Spiegel, M.D.


  • SEC Reporting Status

    SEC Reporting Company
  • CIK

  • Fiscal Year End


Current Share Structure

Current as of 12/31/2010

A/S 350,000,000

O/S 21,242,772 (Mar 28, 2011)

FLOAT  16.48M

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209


 Recent news


Tuesday, August 9, 2011

Wednesday, July 20, 2011

Tuesday, July 19, 2011

Monday, July 18, 2011

Friday, July 1, 2011

Thursday, June 30, 2011

Friday, June 17, 2011

Monday, June 6, 2011

Thursday, May 19, 2011

Friday, May 13, 2011

Tuesday, May 10, 2011

Monday, May 9, 2011

Monday, March 28, 2011

Thursday, March 24, 2011

Monday, March 14, 2011

Thursday, March 10, 2011

Wednesday, January 12, 2011





New presentation from tlon from 3-30-12


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#5999   We should have a class action lawsuits together FLY HIGH NOW 11/14/19 09:52:16 AM
#5998   Yes we should fight for it. I'm still CVR Investor 10/28/19 11:00:25 AM
#5997   We haven’t received any money in our brokers FLY HIGH NOW 10/16/19 01:10:38 PM
#5996   The Spectrum CVR are now renamed to TALON upanddown66 10/16/19 10:50:09 AM
#5995   Still waiting, hopefully we will see something, talk xlofer 09/29/19 06:53:18 PM
#5994   We should have some money back for our FLY HIGH NOW 09/27/19 06:32:56 PM
#5993   R we ever gonna see anything out of SPPI xlofer 08/31/19 02:35:55 AM
#5992   we hope to get our money back soon....we FLY HIGH NOW 07/31/19 12:32:32 PM
#5991   I still hope one day we will get xlofer 07/24/19 12:07:12 AM
#5990   Anyone know any revenues about TLON? where are FLY HIGH NOW 07/22/19 12:12:01 AM
#5989   Anyone knows anything about our money from TLON? FLY HIGH NOW 07/06/19 02:26:20 PM
#5988   Do we ever gonna see our Money. xlofer 01/31/19 12:36:46 AM
#5987   Marqibo sold to Acrotech Biopharma, subsidiary of Aurobindo operating_line 01/23/19 02:20:50 AM
#5986   If you did not receive that cash and operating_line 12/05/18 12:47:53 AM
#5985   My guess is 2020 could be possible but operating_line 12/05/18 12:45:30 AM
#5984   Haven't been here for years. Any help me bmatt 11/29/18 02:08:20 PM
#5983   R we ever will see any Money. Anyone. xlofer 11/29/18 03:18:34 AM
#5982   Spectrum Pharmaceuticals Q3 2018: MARQIBO® net sales operating_line 11/18/18 09:32:04 AM
#5981   CASI Pharmaceuticals To Build GMP Manufacturing Site operating_line 11/17/18 06:21:04 AM
#5980   CASI funding and new CFO operating_line 09/29/18 12:44:41 AM
#5979   You have the CVR payment schedule information from operating_line 08/19/18 05:01:34 AM
#5978   What at least their revenues we Tlon shareholders FLY HIGH NOW 07/31/18 01:25:11 PM
#5977   Q1 2018 MARQIBO® net sales of $0.9 million operating_line 07/08/18 05:23:31 AM
#5976   YES ,we hope Marqibo really help many and FLY HIGH NOW 06/14/18 02:30:17 PM
#5975   CASI have cash reserves to commercialize Marqibo in operating_line 05/22/18 11:12:50 AM
#5974   Q1 2018: Spectrum Pharma- $0.9m net sales Marqibo operating_line 05/22/18 11:04:04 AM
#5973   https://asia.nikkei.com/Business/Trends/China-sees-influx-of-blockbuster-drugs-as-market-grows How FLY HIGH NOW 03/05/18 05:52:58 AM
#5972   Jan 9 2018 report suggests Marqibo to largely operating_line 02/03/18 02:32:12 AM
#5971   I originally hoped 2018 would see the first operating_line 01/02/18 02:15:05 PM
#5970   Would you happen to know when we can CVR Investor 12/13/17 12:25:55 PM
#5969   CVR "Talon.CR" Payment? When can we expect CVR Investor 12/13/17 12:24:24 PM
#5968   Possible new technique to assist opening market for Marqibo operating_line 12/02/17 08:34:27 AM
#5967   we need higher revenues through market expansion operating_line 10/22/17 01:18:39 AM
#5966   Anyone hear anything about revenues on Marquibo? Any FLY HIGH NOW 10/19/17 11:23:41 PM
#5965   what are new with the sppi thiefs.... share upanddown66 10/17/17 01:35:44 PM
#5964   we got any positive news?? I hope they FLY HIGH NOW 07/05/17 09:30:27 PM
#5963   Two MARQIBO related abstracts of Clinical Data at operating_line 06/30/17 04:13:50 AM
#5962   Ongoing Study: Marqibo in combination with UK ALL R3 operating_line 05/09/17 11:28:13 PM
#5961   Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results operating_line 05/09/17 11:15:05 PM
#5960   I think more tham 7 mil revenues for FLY HIGH NOW 03/21/17 03:01:20 PM
#5959   I think more tham 7 mil revenues for FLY HIGH NOW 03/21/17 03:01:19 PM
#5958   Hey I am waiting as well if you xlofer 03/14/17 11:21:29 PM
#5957   Anyone know how much for total revenues for FLY HIGH NOW 03/12/17 03:07:48 PM
#5956   taken from q3 2016 SPPI: upanddown66 12/20/16 08:01:21 AM
#5955   they not pay quarterly CVRs? or annual payouts FLY HIGH NOW 08/18/16 10:23:18 PM
#5954   No choice but to wait...I suspect annual CVR operating_line 08/18/16 07:38:54 AM
#5953   How much at least Marqibo net sale...so we FLY HIGH NOW 08/14/16 11:26:43 PM
#5952   Pipeline Drug operating_line 08/11/16 05:12:07 AM
#5951   Q2 2016 sales flat: MARQIBO® net sales of operating_line 08/11/16 05:04:56 AM
#5950   http://www.nasdaq.com/article/spectrum-sppi-incurs-narrower-than-expected-loss-in-q4-cm591425 Mar operating_line 03/21/16 09:26:34 AM